DURECT Corporation (DRRX) Stock Rating Reaffirmed by HC Wainwright

DURECT Corporation (NASDAQ:DRRX)‘s stock had its “hold” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday.

A number of other brokerages have also recently commented on DRRX. Stifel Nicolaus cut DURECT Corporation from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. ValuEngine upgraded DURECT Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Laidlaw lowered their target price on DURECT Corporation from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, October 20th.

Shares of DURECT Corporation (NASDAQ:DRRX) traded up $0.08 on Thursday, hitting $0.95. The stock had a trading volume of 2,062,299 shares, compared to its average volume of 1,459,119. DURECT Corporation has a one year low of $0.74 and a one year high of $2.17. The company has a debt-to-equity ratio of -9.08, a current ratio of 1.53 and a quick ratio of 1.39.

DURECT Corporation (NASDAQ:DRRX) last announced its quarterly earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.09. DURECT Corporation had a negative return on equity of 638.84% and a negative net margin of 62.57%. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $5.09 million. analysts expect that DURECT Corporation will post -0.14 EPS for the current year.

WARNING: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.com-unik.info/2017/11/05/durect-corporation-drrx-stock-rating-reaffirmed-by-hc-wainwright.html.

A number of large investors have recently made changes to their positions in DRRX. Ingalls & Snyder LLC raised its position in DURECT Corporation by 213.1% during the 2nd quarter. Ingalls & Snyder LLC now owns 6,419,482 shares of the specialty pharmaceutical company’s stock worth $10,014,000 after purchasing an additional 4,369,400 shares during the last quarter. Asymmetry Capital Management L.P. bought a new position in shares of DURECT Corporation in the 2nd quarter worth about $1,636,000. Tocqueville Asset Management L.P. raised its position in shares of DURECT Corporation by 70.3% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 2,043,383 shares of the specialty pharmaceutical company’s stock worth $3,617,000 after acquiring an additional 843,383 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of DURECT Corporation by 13.4% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,175,994 shares of the specialty pharmaceutical company’s stock worth $4,955,000 after acquiring an additional 374,618 shares in the last quarter. Finally, Mangrove Partners bought a new position in shares of DURECT Corporation in the 2nd quarter worth about $530,000. 45.91% of the stock is owned by institutional investors and hedge funds.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

What are top analysts saying about DURECT Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DURECT Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit